Literature DB >> 14633736

Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion.

Ganesan Sathya1, Ching-yi Chang, Dmitri Kazmin, C Edgar Cook, Donald P McDonnell.   

Abstract

The androgen receptor (AR), a member of the nuclear receptor family, is a ligand-inducible transcription factor. In the prostate gland, androgens regulate the transcription of several genes that ultimately result in cell growth and differentiation. With a goal of developing tissue-selective AR modulators that can be used to treat prostate cancer and other androgenopathies, we have taken an approach to identify androgens that function in a manner distinct from the physiological androgens testosterone and dihydrotestosterone. Classical AR agonists function by binding to and inducing a conformational change in the receptor. This facilitates the obligate interaction of the amino and carboxyl terminus of the receptor, recruitment of coactivators, and subsequent regulation of target genes. On the basis of this paradigm, we screened a library of potential AR agonists for compounds that induce an "activating" conformational change in the receptor structure but that do not facilitate a high-affinity intermolecular interaction between the amino and carboxyl terminus. Compounds identified in this manner behaved as partial agonists of AR-mediated transcription in a variety of assays. Additional compounds were identified in this screen that did not allow the activation function-2 coactivator pocket to form and were demonstrated to function as weak agonists of AR-mediated transcription. Surprisingly, when we examined the ability of these compounds to induce cell proliferation, we observed that despite having different degrees of partial agonist activities on classical transcriptional responses (i.e., induction of prostate-specific antigen), these compounds were as efficacious as dihydrotestosterone in stimulating proliferation. The unexpected finding that AR-mediated transcription and proliferation can be uncoupled suggests that AR is not used in the same manner in all androgen-regulated biological processes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633736

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Chemistry and structural biology of androgen receptor.

Authors:  Wenqing Gao; Casey E Bohl; James T Dalton
Journal:  Chem Rev       Date:  2005-09       Impact factor: 60.622

Review 2.  Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging.

Authors:  Shalender Bhasin; Olga M Calof; Thomas W Storer; Martin L Lee; Norman A Mazer; Ravi Jasuja; Victor M Montori; Wenqing Gao; James T Dalton
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2006-03

3.  Hormonal control of androgen receptor function through SIRT1.

Authors:  Maofu Fu; Manran Liu; Anthony A Sauve; Xuanmao Jiao; Xueping Zhang; Xiaofang Wu; Michael J Powell; Tianle Yang; Wei Gu; Maria Laura Avantaggiati; Nagarajan Pattabiraman; Timothy G Pestell; Fang Wang; Andrew A Quong; Chenguang Wang; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2006-08-21       Impact factor: 4.272

Review 4.  Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).

Authors:  Wenqing Gao; James T Dalton
Journal:  Drug Discov Today       Date:  2007-02-07       Impact factor: 7.851

5.  Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.

Authors:  Irina U Agoulnik; William E Bingman; Manjula Nakka; Wei Li; Qianben Wang; X Shirley Liu; Myles Brown; Nancy L Weigel
Journal:  Mol Endocrinol       Date:  2008-09-11

Review 6.  Selective androgen receptor modulators as function promoting therapies.

Authors:  Shalender Bhasin; Ravi Jasuja
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2009-05       Impact factor: 4.294

7.  The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.

Authors:  Kongming Wu; Sanjay Katiyar; Agnes Witkiewicz; Anping Li; Peter McCue; Liang-Nian Song; Lifeng Tian; Ming Jin; Richard G Pestell
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  Differential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands.

Authors:  John David Norris; James David Joseph; Andrea Barreto Sherk; Dalia Juzumiene; Philip Stewart Turnbull; Stephen William Rafferty; Huaxia Cui; Erin Anderson; Daju Fan; Delita Arnelle Dye; Xiang Deng; Dmitri Kazmin; Ching-Yi Chang; Timothy Mark Willson; Donald Patrick McDonnell
Journal:  Chem Biol       Date:  2009-04-24

9.  RNA editing of androgen receptor gene transcripts in prostate cancer cells.

Authors:  Harryl D Martinez; Rohini J Jasavala; Izumi Hinkson; Latricia D Fitzgerald; James S Trimmer; Hsing-Jien Kung; Michael E Wright
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

10.  Identification of Androgen Receptor Modulators in a Prostate Cancer Cell Line Microarray Compendium.

Authors:  John P Rooney; Brian Chorley; Nicole Kleinstreuer; J Christopher Corton
Journal:  Toxicol Sci       Date:  2018-11-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.